leon-nanodrugs appoints Dr. Wolfgang Hofmann as Chief Executive Officer
leon-nanodrugs GmbH (LEON), a German Pharmatech company, is pleased to announce the appointment of Dr. Wolfgang Hofmann as its new Chief Execu ve Officer (CEO), effec ve immediately. With his extensive experience in scaling life science ventures and leading interna onal teams, Dr. Hofmann will guide LEON through its next phase of growth. Under his leadership, LEON will focus on bringing its breakthrough FR-JET® technology and equipment por olio to the market. The company is now entering a pivotal phase, transi oning from development to commercializa on. In the coming months, LEON aims to establish key partnerships, expand manufacturing capabili es, and posi on itself as a leading enabler of high quality GMP nanopar cle manufacturing.
Dr. Wolfgang Hofmann, CEO leon-nanodrugs GmbH.
© LEON
Dr. Hofmann brings 30 years of experience in medicine, medical research, corporate strategy, financing, and opera onal management within the pharmaceu cal and medical technology industries. He began his career at Dana-Farber Cancer Ins tute and Harvard Medical School, contribu ng to early gene therapy systems. He later held senior posi ons at Novar s and execu ve roles at Fresenius Group, covering M&A, venture capital, and innova on management. As an entrepreneur, he has founded companies and supports nonprofit ins tu ons. Dr. Hofmann holds a medical doctorate from the University of Heidelberg and an execu ve management degree from Harvard Business School.
“I am thrilled to be appointed CEO and to work with the outstanding team at LEON,” Hofmann said. “LEON brings market-ready systems for the manufacturing of the most advanced lipid- and polymerbased nanopar cles, as well as nanoprecipita on – used in the pharma and biotech sectors and other high-tech fields where process quality and control are essen al. I am confident that LEON’s game changing systems will transform these fields in quality, cost, and convenience in the near future.”
Dr. Hubert Birner, Chairman of the LEON Supervisory Board, said: “We are excited to appoint Dr. Hofmann as the new CEO of LEON. Dr. Hofmann brings key skills and global experience to take LEON to the next level of development. This includes the crea on of partnerships and strategic op ons for the company, as well as the commercializa on of our exci ng product range. We are confident that our fully developed technology will serve pharmaceu cal and other manufacturers around the world to reach new levels of efficiency in development of their LNP- or PNP-based projects and bring to market superior products based on our pla orms.”
Other news from the department people
These products might interest you
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.